5HT₃RA plus dexamethasone plus aprepitant for controlling delayed chemotherapy-induced nausea and vomiting in colorectal cancer

Toshinobu Hayashi¹ | Mototsugu Shimokawa²,³ | Koichi Matsuo¹,⁴ | Junichi Nishimura⁵ | Hirotsuhi Iihara⁶ | Takafumi Nakano¹ | Takashi Egawa¹

Abstract

Delayed chemotherapy-induced nausea and vomiting (CINV) is not well controlled in colorectal cancer (CRC) patients undergoing oxaliplatin (L-OHP)-based chemotherapy. Whether neurokinin-1 receptor antagonist addition to a first-generation 5HT₃ antagonist (1st 5-HT₃RA) and dexamethasone (DEX) is beneficial to these patients remains controversial. Furthermore, whether palonosetron (PALO) or aprepitant (APR) is more effective in controlling delayed CINV is unclear. We, therefore, investigated whether PALO+DEX or 1st 5-HT₃RA+DEX+APR was more effective in controlling delayed CINV, and the risk factors for delayed CINV, in CRC patients undergoing L-OHP-based chemotherapy. Data were pooled from two prospective observational Japanese studies and a phase III trial to compare CINV incidence between the PALO+DEX (PALO) and 5-HT₃RA+DEX+APR (APR) groups by propensity score-matched analysis. CINV risk factors were identified using logistic regression models. The CINV incidence was higher in the PALO group than in the APR group. Logistic regression analysis revealed alcohol consumption, motion sickness, and the PALO+DEX regimen as independent risk factors for delayed nausea, and female sex and the PALO+DEX regimen as those for delayed vomiting. Compared with prophylactic PALO+DEX, 1st 5-HT₃RA+DEX+APR was more effective in controlling delayed CINV. Thus, CRC patients receiving L-OHP-based chemotherapy should be treated with three antiemetics, including APR.

Keywords

aprepitant, colorectal cancer, nausea, oxaliplatin, vomiting

Abbreviations: 5-HT₃Ras, 5-hydroxytryptamine-3 receptor antagonists; APR, aprepitant; CAPOX, capecitabine plus oxaliplatin; CINV, chemotherapy-induced nausea and vomiting; CRC, colorectal cancer; DEX, dexamethasone; ESMO, European Society for Medical Oncology; FOLFOX, fluorouracil plus leucovorin plus oxaliplatin; GRA, granisetron; HEC, high-emetic-risk chemotherapy; L-OHP, oxaliplatin; MEC, moderate-emetic-risk chemotherapy; MST, median survival time; NK1Ras, neurokinin-1 receptor antagonists; OLZ, olanzapine; PALO, palonosetron; RCT, randomized controlled trial.
Colorectal cancer (CRC) is one of the most common cancers worldwide. In the late 1990s, oxaliplatin (L-OHP), one of the key drugs for CRC treatment, was developed, and the 5-fluorouracil plus leucovorin plus oxaliplatin (FOLFOX) and capcitabine plus oxaliplatin (CAPOX) regimes were established. Thus far, these regimes have remained the standard cytotoxic drug combinations to provide approximately 20 months or more of median survival time (MST). New molecular targeting agents have been continuously developed, and in combination with cytotoxic drugs such as L-OHP, they provide longer survival, i.e., more than 30 months of MST. It is important to note that the improvement in survival has been achieved not only with the development of antitumor agents but also with the development of supportive care.

Chemotherapy-induced nausea and vomiting (CINV) is one of the major adverse events during cancer chemotherapy. With the development of effective antiemetic agents such as 5-hydroxytryptamine-3 receptor antagonists (5-HT3RAs) and neurokinin-1 receptor antagonists (NK1RAs), the management of CINV has been improving. Palonosetron (PALO) is a second-generation 5-HT3RA indicated for the prevention of both acute and delayed CINV. It has a higher affinity for the 5-HT3 receptor and longer half-life than first-generation (1st) 5-HT3RAs. It has been proven superior to 1st 5-HT3RAs in clinical trials conducted among patients receiving both moderate-emetic-risk chemotherapy (MEC) and high-emetic-risk chemotherapy (HEC).

Aprepitant (APR) is a selective NK1RA. Several studies have demonstrated that adding APR to doublet antiemetic therapy with a 5-HT3RA and dexamethasone (DEX) can control CINV in HEC regimes. However, in a nationwide, prospective, observational multicenter study, the incidences of delayed nausea and vomiting in CRC patients receiving L-OHP-based chemotherapy were 37.9% and 12.6%, respectively. In a multicenter, randomized controlled trial (RCT) in CRC patients treated with L-OHP-based chemotherapy (SENRI trial), the “no nausea” rates of doublet antiemetic prophylaxis and triplet antiemetic prophylaxis including APR were 61.8% and 66.3%, respectively. In another RCT, the delayed total control (no vomiting, no nausea, and no rescue medication) rate was 48.1% with PALO+DEX. Delayed CINV reduces patients’ quality of life, and remains a major problem for many CRC patients receiving L-OHP-based chemotherapy.

In the SENRI trial, complete response and protection in the delayed phase were achieved significantly more often in the triplet group than in the doublet group (85.0% vs 75.4%, and 79.7% vs 69.4%, respectively). Kitayama et al reported that PALO+DEX showed equivalent antiemetic efficacy compared with that of APR plus granisetron (GRA) plus DEX in MEC in a prospective randomized crossover study. Tsuji et al suggested that patients receiving L-OHP-based regimens seem to benefit from doublet therapy involving PALO or triplet therapy involving APR. These results suggest that patients receiving L-OHP-based regimens need doublet or triplet antiemetic prophylaxis with PALO or APR, respectively. However, it is unclear whether PALO or APR is more effective in controlling delayed CINV in CRC patients receiving L-OHP-based chemotherapy. Therefore, in this study, we investigated whether PALO+DEX or 1st 5-HT3RA+DEX+APR was more effective in controlling delayed CINV, as well as the risk factors for delayed CINV, in CRC patients treated with L-OHP-based chemotherapy.

2 | MATERIALS AND METHODS

2.1 | Study design

Pooled data of 404 patients who participated in two multicenter, prospective observational studies and one randomized trial were analyzed. Individual study results were previously published or presented at the annual meeting of the European Society for Medical Oncology (ESMO). The study flowchart is shown in Figure 1. The studies were conducted in patients who were scheduled to receive L-OHP-based chemotherapy (FOLFOX or CAPOX) in Japan and were approved by the institutional review board or independent ethics committee of the sites involved in the studies. Written informed consent was obtained from all participating patients before any related study procedure was initiated. All procedures performed were in accordance with the ethical standards of the institutional research committee and the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

2.2 | Data collection

Any nausea and vomiting developing within 24 hours after chemotherapy was defined as acute CINV, while nausea and vomiting developing between 24 hours and 7 days after the start of the chemotherapy as delayed CINV. Patients enrolled in any of the three studies were required to be at least 20 years of age, have CRC, and be chemotherapy-naïve. Data collection included data from the 7-day diaries started by the patients on the day of chemotherapy; the CINV data were based on patient self-reports in the diaries. Eligible patients received an L-OHP-based regimen as chemotherapy, and PALO + DEX (PALO group) or 1st 5-HT3RA + DEX+APR (APR group) as antiemetic prophylaxis, which was administered within 1 h before the scheduled chemotherapy.

2.3 | Statistical analysis

Patient demographics and the incidence of CINV were analyzed using descriptive statistics (Chi-square test). Propensity score matching was used to reduce the imbalance between the PALO and APR groups. Propensity scores to determine matched pairs between the groups were obtained using five variables (age, sex, drinking habit, a history of motion sickness, and antiemetic prophylaxis) that could potentially influence the development of CINV among patients with
lung cancer. The scores were evaluated using a logistic regression model in this study. Patients were matched at a 1:1 ratio by using the caliper matching method within 0.2 of the standard deviation from the propensity score logit.

Independent risk factors for CINV were evaluated using logistic regression analysis with the backward elimination method. \( P < .05 \) (two-sided) was considered significant, except for independent risk factors (significance level was \( P < .1 \)). All statistical analyses were performed using SAS 9.4 (SAS Institute).

3 | RESULTS

3.1 | Patient characteristics

A total of 272 patients were included in the analysis: 136 received PALO+DEX and 136 received 1st 5-HT3RA+DEX+APR. Patients’ baseline characteristics, including sex, age, motion sickness, and drinking habits, are shown in Table 1.

3.2 | Propensity score matching analysis

Propensity score matching was used to adjust for differences in the patients’ baseline characteristics that could potentially influence the development of CINV between the two groups. The matching was done at a ratio of 1:1, and we obtained the score-matched pairs for subsequent analyses. After propensity score matching, variables between the two groups were found to not be significantly different (Table 1).

3.3 | Control of CINV

The propensity score–matched incidence patterns of nausea and vomiting after chemotherapy are shown in Figure 2. The incidence of delayed vomiting significantly differed between the PALO and APR groups (12.5% vs 4.4%, \( P = .017 \)). The incidence of nausea did not significantly differ between the PALO group (43.4%) and the APR group (32.4%).

3.4 | Risk factors for CINV

The results of the univariate and multivariate logistic regression analyses of risk factors for delayed CINV are shown in Table 2. Sex, age, drinking habits, motion sickness, and antiemetic prophylaxis were analyzed. Motion sickness, drinking habit, and the PALO+DEX regimen were identified as risk factors for delayed nausea, while female sex and the PALO+DEX regimen were identified as risk factors for delayed vomiting.

4 | DISCUSSION

In the present study, we evaluated whether PALO or APR was useful for preventing delayed CINV in CRC patients treated with L-OHP-based chemotherapy. Compared with prophylaxis with PALO+DEX, prophylaxis with 1st 5-HT3RA+DEX+APR significantly reduced the incidence of delayed vomiting. Along with female sex, the PALO+DEX regimen was identified as a risk factor for delayed vomiting. Although there was no significant difference in the incidence
of delayed nausea between the two groups, the PALO+DEX regimen was identified as a risk factor for delayed nausea, along with motion sickness and drinking habit.

The benefit of adding NK1RAs to a conventional doublet antiemetic prophylaxis remains controversial for MECs other than carboplatin-based regimens, and recommendations for using NK1RAs with MEC vary among guidelines.\textsuperscript{23-25} Because few clinical trials have attempted to determine the optimal antiemetic prophylaxis for CRC patients receiving L-OHP-based regimens, evidence-based guidance in this setting is lacking.

Hesketh et al\textsuperscript{26} reported that the addition of single-dose casopitant did not improve the overall control of CINV in patients receiving L-OHP-based MEC. Excellent control of CINV was achieved with the combination of ondansetron and DEX in this study population. On the other hand, Nishimura et al\textsuperscript{17} reported that triplet antiemetic prophylaxis including APR was more effective than doublet antiemetic prophylaxis in preventing CINV in CRC patients receiving L-OHP-based regimens. In addition, the overall antiemetic effects of APR with or without PALO did not significantly differ. A recent meta-analysis\textsuperscript{27} indicated that the addition of NK1RAs for patients undergoing L-OHP-based chemotherapy did not have a very pronounced effect. However, the two major studies cited above\textsuperscript{17,26} that included CRC patients with similar L-OHP doses showed conflicting results. In the study by Hesketh et al,\textsuperscript{26} the use of casopitant instead of APR may also have affected the difference in results. There are other reports that PALO+DEX or triplet antiemetic prophylaxis with APR is needed to control delayed CINV in patients receiving L-OHP-based chemotherapy.\textsuperscript{16,20} A 10% absolute difference in the rates of nausea and vomiting seems to be clinically meaningful to the patient as defined by Multinational Association of Supportive Care in Cancer/ESMO.\textsuperscript{28} In this study, the APR regimens reduced the incidence of delayed vomiting by 8.09% and that of delayed nausea by 11.03%, compared with the PALO group.

In this study, patients receiving 1-day DEX, not multi-day (3 or 4 days) DEX, accounted for 9.5% and 14.9% of the patients in the APR and PALO groups, respectively. A DEX-sparing strategy of antiemetic prophylaxis consisting of PALO + 1-day DEX for the prevention of CINV has been studied previously.\textsuperscript{18,29,30} A meta-analysis\textsuperscript{31} indicated that a DEX-sparing antiemetic regimen was not associated

| TABLE 1 Patient characteristics |
|---------------------------------|
|                                |
| Before propensity score matching |
| PALO group                      |
| (N = 266)                       |
| Sex                             |
| Male                            |
| 154 (57.9)                      |
| Female                          |
| 112 (42.1)                      |
| Age, years                      |
| <60                             |
| 104 (39.1)                      |
| ≥60                             |
| 162 (60.9)                      |
| Motion sickness                 |
| No                              |
| 228 (85.7)                      |
| Yes                             |
| 34 (12.8)                       |
| Drinking habit                  |
| No                              |
| 160 (60.2)                      |
| Yes                             |
| 104 (39.1)                      |

| After propensity score matching |
| PALO group                      |
| (N = 138)                       |
| Sex                             |
| Male                            |
| 81 (58.7)                       |
| Female                          |
| 57 (41.3)                       |
| Age, years                      |
| <60                             |
| 40 (29.0)                       |
| ≥60                             |
| 98 (71.0)                       |
| Motion sickness                 |
| No                              |
| 116 (84.1)                      |
| Yes                             |
| 22 (15.9)                       |
| Drinking habit                  |
| No                              |
| 108 (78.3)                      |
| Yes                             |
| 28 (20.3)                       |

Abbreviations: APR, aprepitant; PALO, palonosetron.
with a significant loss in antiemetic control in patients undergoing MEC including L-OHP–based regimens, irrespective of the known risk factors for CINV. Therefore, differences in the dosing period of DEX do not appear to affect the results of this study.

Triplet antiemetic prophylaxis including APR has been reported to be promising from an economic perspective in Japan. Toda et al. reported that the antiemetic efficacy and cost-effectiveness of a three-drug combination involving APR, generic GRA, and DEX was superior to those of a two-drug combination involving PALO and DEX in patients who received MEC. Risk/benefit profiles and medication costs are important factors influencing treatment decisions, including antiemetic treatment.

The assessment of individual risk factors is an important step in the development of personalized treatments for CINV. Younger age, female sex, motion sickness, and a drinking habit are well-known patient-related risk factors for CINV. Therefore, differences in the dosing period of DEX do not appear to affect the results of this study.

In the present study, a drinking habit and history of motion sickness were identified as patient-related risk factors for CINV. Therefore, differences in the dosing period of DEX do not appear to affect the results of this study.

In patients receiving MEC, PALO and 1st 5-HT3RA might have an equivalent effect on CINV control when used in combination with NK1RA and DEX. Improvement in antiemetic treatments involving combinations of antiemetic agents with different mechanisms of action, such as olanzapine (OLZ), is needed for patients in whom risk factors for CINV have been identified.

OLZ is classified as a multiacting receptor-targeted antipsychotic that blocks dopamine D1, D2, D3, and D4 receptors; 5-TH2A, 5-HT2B, 5-HT3, and 5-HT6 receptors; histamine H1 receptors; and muscarinic acetylcholine receptors M1, M2, M3, and M4. OLZ activity at multiple receptors that may be involved in nausea and vomiting suggests that it might have clinically significant antiemetic properties. Navari et al. revealed that the use of OLZ 10 mg significantly improved nausea prevention as well as the complete response rate among patients who were receiving HEC. Hashimoto et al. reported that OLZ 5 mg combined with APR, PALO, and DEX was more effective compared with placebo combined with these agents in patients undergoing cisplatin-based chemotherapy. Although the evidence on the effectiveness of OLZ for CINV management in MEC is insufficient, more aggressive antiemetic treatment options such as quadruple therapy including OLZ may be considered for these patients.

The present study has some limitations. First, it is not a blind RCT. Second, risk factors such as smoking habit and morning sickness could not be analyzed. Finally, the results of this study were obtained from the Japanese population. However, they are likely applicable to other Asian populations. Further research is needed to verify whether these results could be extrapolated to other populations. Despite these limitations, the findings indicate the basic antiemetic prophylaxis for L-OHP–based chemotherapy. Because data with a sufficient number of events from three prospective studies including an RCT have been analyzed using propensity score–matched analysis, it is considered to be of high quality.

### TABLE 2 Risk factors for delayed nausea and vomiting

|                     | Delayed nausea |                      | Delayed vomiting |                      |
|---------------------|----------------|----------------------|------------------|----------------------|
|                     | Univariate     | Multivariate        | Univariate       | Multivariate        |
|                     | OR (95% CI)    | P-value              | OR (95% CI)      | P-value              |
| Sex                 |                |                      |                  |                      |
| Female vs male      | 1.792 (1.196-2.685) | 0.005               | 3.426 (1.790-6.558) | <0.001               |
| Age, years <60 vs ≥ 60 | 1.360 (0.900-2.056) | 0.145               | 1.392 (0.750-2.582) | 0.294               |
| Drinking habit No vs yes | 1.628 (1.052-2.520) | 0.029               | 1.941 (1.227-3.072) | 0.005               |
| Yes vs no Motion sickness | 2.391 (13.45-4.251) | 0.003               | 2.606 (1.444-4.703) | 0.002               |
| Antiemetics         |                |                      |                  |                      |
| PALO group vs APR group | 1.570 (1.023-2.411) | 0.039               | 1.983 (1.257-3.129) | 0.003               |

Abbreviations: APR, aprepitant; CI, confidence interval; OR: odds ratio; PALO, palonosetron.
In conclusion, treatment with the triplet antiemetic prophylaxis, involving APR, was more effective in controlling delayed CINV than prophylaxis with PALO+DEX. Thus, CRC patients receiving L-OHP-based chemotherapy should be treated with three antiemetics, including APR.

ACKNOWLEDGEMENTS
We wish to thank Dr Kazuo Tamura for support as the principal investigator of study A, and Dr Koichi Goto and Ms Reiko Matsui for support as the principal investigators of study B. We also would like to thank all the study participants of the aforementioned studies and their families.

DISCLOSURE
The authors declare that they have no conflicts of interest. Furthermore, this research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

ORCID
Toshinobu Hayashi https://orcid.org/0000-0001-6183-4939

REFERENCES
1. World Health Organization. Cancer fact sheet. Updated September 2018. https://www.who.int/en/news-room/fact-sheets/detail/cancer. Accessed June 18, 2020
2. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229-237. https://doi.org/10.1200/JCO.2004.05.113
3. Yamazaki K, Nagase M, Tamagawa H, et al. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol. 2016;27:1539-1546.
4. Yang LP, Scott LJ. Palonosetron: in the prevention of nausea and vomiting. Drugs. 2009;69:2257-2278.
5. Stolitz R, Cyong JC, Shah A, Parisi S. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J Clin Pharmacol. 2004;44:520-531.
6. Rojas C, Thomas AG, Alt J, et al. Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol. 2010;626:193-199.
7. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14:1570-1577.
8. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003;98:2473-2482.
9. Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 2006;17:1441-1449.
10. Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009;10:115-124.
11. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358:2482-2494.
12. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97:3090-3098.
13. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 receptor aprepatient for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21:4112-4119.
14. Schmoll HJ, Aapro MS, Poli-Bigelli S, et al. Comparison of an aprepatient regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol. 2006;17:1000-1006.
15. Jordan K, Warr DG, Hinke A, Sun L, Hesketh PJ. Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings—a meta-analysis. Support Care Cancer. 2016;24:1941-1954.
16. Tsuji Y, Baba H, Takeda K, et al. Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan. Expert Opin Pharmacother. 2017;18:753-758.
17. Nishimura J, Satoh T, Fukunaga M, et al. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. Eur J Cancer. 2015;51:1274-1282.
18. Komatsu Y, Okito K, Yuki S, et al. Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with palonosetron. Cancer Sci. 2015;106:891-895.
19. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24:4472-4478.
20. Kitayama H, Tsuji Y, Sugiyama J, Doi A, Kondo T, Hirayama M. Efficacy of palonosetron and 1-day dexamethasone in moderately emetogenic chemotherapy compared with fosaprepitant, granisetron, and dexamethasone: a prospective randomized crossover study. Int J Clin Oncol. 2015;20:1051-1056.
21. Tamura K, Aiba K, Saeki T, et al. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol. 2015;20:855-865.
22. Matsui R, Suzuki K, Takiguchi T, et al. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy induced nausea and vomiting during moderately emetogenic chemotherapy for solid tumors: A multicenter, prospective, observational study. BMC Pharmacol Toxicol. 2020;21:72.
23. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (2020) Antiemetics. Version 1. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Accessed February 19, 2020
24. Rola F, Warr D, Hesketh PJ, et al. 2016 Updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following moderately emetogenic chemotherapy. Support Care Cancer. 2017;25:289-294.
25. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol*. 2017;35:3240-3261.

26. Hesketh PJ, Wright O, Rosati G, et al. Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study. *Support Care Cancer*. 2012;20:1471-1478.

27. Jordan K, Blättermann L, Hinke A, Müller-Tidow C, Jahn F. Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy? a systematic review and meta-analysis. *Support Care Cancer*. 2018;26:21-32.

28. Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. *Ann Oncol*. 2010;21:v232-243.

29. Celio L, Frustaci S, Denaro A, et al. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. *Support Care Cancer*. 2011;19:1217-1225.

30. Furukawa N, Kanayama S, Tanase Y, Ito F. Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin. *Support Care Cancer*. 2015;23:3317-3322.

31. Okada Y, Oba K, Furukawa N, et al. One-day versus three-day dexamethasone in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and individual patient data-based meta-analysis. *Oncologist*. 2019;24:1593-1600.

32. Toda H, Kawazoe H, Yano A, et al. Antiemetic effectiveness and cost-saving of aprepitant plus granisetron is superior to palonosetron in gastrointestinal cancer patients who received moderately emetogenic chemotherapy. *J Cancer*. 2017;8:1371-1377.

33. Sekine I, Segawa Y, Kubota K, Saeki T. Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. *Cancer Sci*. 2013;104(6):711-717.

34. Takemoto H, Nishimura J, Komori T, et al. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea. *Int J Clin Oncol*. 2017;22:88-95.

35. Molassiotis A, Aapro M, Dicato M, et al. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. *J Pain Symptom Manag*. 2014;47(839–848):e4.

36. Zhang Y, Yang Y, Zhang Z, et al. Neurokinin-1 receptor antagonist-based triple regimens in preventing chemotherapy-induced nausea and vomiting: A network meta-analysis. *J Natl Cancer Inst*. 2017;109.

37. Navari RM, Qin R, Ruddy KJ, et al. Olanzpine for the prevention of chemotherapy-induced nausea and vomiting. *N Engl J Med*. 2016;375:134-142.

38. Hashimoto H, Abe M, Tokuyama O, et al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2020;21:242-249.